Jieming Zeng

Title: Jieming Zeng: Innovator in Immune Cell Therapy

Introduction

Jieming Zeng is a prominent inventor based in Singapore, known for his groundbreaking work in the field of immunotherapy. He has been instrumental in developing methods to generate mimetic innate immune cells from pluripotent stem cells, which hold great promise for cancer treatment. With a total of 3 patents to his name, Zeng's contributions are paving the way for innovative therapeutic approaches.

Latest Patents

Zeng's latest patents include significant advancements in the generation of immune cells. One of his notable inventions focuses on methods for generating mimetic innate immune cells from human pluripotent stem cells (hPSCs). This invention outlines a robust protocol for differentiating hPSCs into natural killer (NK) cells and γδ T-cells, which are crucial for cancer immunotherapy. The protocol allows for consistent mass production of these cells without the need for CD34+ cell enrichment, demonstrating a significant leap in the field.

Another patent involves gamma delta T cells and a method to enhance their tumoricidal activity. This method includes culturing γδ T cells with phosphoantigens to expand their population and subsequently with artificial antigen-presenting cells. This innovative approach not only generates effective γδ T cells but also opens new avenues for treatment and medical applications.

Career Highlights

Jieming Zeng is affiliated with the Agency for Science, Technology and Research, where he continues to push the boundaries of immunological research. His work has garnered attention for its potential to revolutionize cancer therapies through the use of engineered immune cells. Zeng's dedication to advancing medical science is evident in his innovative research and patent contributions.

Collaborations

Zeng collaborates with esteemed colleagues such as Shu Wang and Shan Shan Wu, who share his vision of enhancing cancer treatment through innovative immune cell therapies. Their combined expertise fosters a collaborative environment that drives forward-thinking research.

Conclusion

Jieming Zeng's contributions to the field of immunotherapy through his patents and research are significant. His innovative methods for generating immune cells from pluripotent stem cells represent a promising frontier in cancer treatment. As he continues to collaborate with other experts, the impact of his work is likely to grow, offering hope for improved therapeutic strategies in the fight against cancer.